Concept Architecture
Incremental net monetary benefit
This page explains how incremental net monetary benefit, usually shortened to INMB, combines incremental costs, incremental health outcomes and a cost-effectiveness threshold in one calculation. It also explains how to interpret positive, zero and negative results, compare several alternatives and distinguish cost-effectiveness from affordability.
What INMB tells us
INMB shows whether the additional health produced by an intervention is worth more or less than its additional cost at a stated threshold. Unlike an ICER, INMB is expressed as a monetary value and does not require division by incremental effectiveness.
A positive INMB favours the intervention under the stated cost-effectiveness rule. A negative INMB favours the comparator, while an INMB of zero means that the two alternatives are tied under that rule.
The information needed for the calculation
The calculation requires incremental cost, incremental effectiveness and a cost-effectiveness threshold. All three inputs must refer to the same comparison, population, analytical perspective, time horizon and decision context.
- Incremental cost is the intervention’s cost minus the comparator’s cost.
- Incremental effectiveness is the intervention’s outcome minus the comparator’s outcome.
- The threshold states the monetary value assigned to one additional unit of outcome for the decision.
How INMB is calculated
INMB first values the incremental health outcome using the threshold and then subtracts incremental cost. The result represents the net monetary value of choosing the intervention instead of the comparator.
INMB = (λ × ΔE) − ΔC
where:
- λ is the cost-effectiveness threshold;
- ΔE is incremental effectiveness; and
- ΔC is incremental cost.
A worked healthcare example
Suppose a new treatment produces 0.40 additional QALYs and costs £6,000 more than current care. At a threshold of £20,000 per QALY, the additional health is valued at £8,000.
INMB = (£20,000 × 0.40) − £6,000
INMB = £8,000 − £6,000 = £2,000
The positive INMB means that the new treatment provides greater expected net monetary benefit than current care at the £20,000 threshold. It does not mean that the treatment is affordable or that it must be adopted.
How to interpret the result
The sign of INMB gives a direct comparison between the intervention and comparator at the stated threshold. The size of the result shows how far apart the alternatives are under that particular decision rule.
- Positive INMB: The intervention is preferred on expected cost-effectiveness grounds.
- Zero INMB: The alternatives are tied under the stated threshold.
- Negative INMB: The comparator is preferred on expected cost-effectiveness grounds.
Why the threshold matters
Changing the threshold changes the monetary value assigned to incremental health outcomes and can therefore change the preferred alternative. An INMB result must always be reported with the threshold used to calculate it.
A threshold is not a universal price for health and should not be transferred automatically between health systems. Its interpretation depends on the jurisdiction, decision process and underlying view of opportunity cost.
How INMB relates to an ICER
An ICER reports additional cost per additional unit of outcome, while INMB converts costs and outcomes into a single monetary measure at a stated threshold. Both use the same incremental evidence, but they organise and present that evidence differently.
INMB avoids division by zero and the ambiguity of negative ICERs. It also allows dominated and threshold-dependent results to be evaluated using one consistent decision rule.
Comparing more than two alternatives
When several alternatives are available, calculate expected net monetary benefit for each alternative using the same threshold and analytical assumptions. The alternative with the greatest expected net monetary benefit is preferred under the economic decision rule.
Pairwise INMB can explain the difference between two specified alternatives. For the full decision, comparing total expected net benefit across every relevant alternative is generally clearer than relying on several disconnected pairwise ratios.
How uncertainty affects INMB
Costs, outcomes and model assumptions are uncertain, so the calculated INMB is also uncertain. Probabilistic analysis can estimate expected net benefit and show how often each alternative produces the highest net benefit across simulations.
The probability that an intervention is cost-effective is not the same as its expected net benefit. The decision rule selects the alternative with the greatest expected net benefit, while the probability describes uncertainty about which alternative performs best.
Why positive INMB does not guarantee adoption
Positive INMB supports a cost-effectiveness conclusion at the stated threshold. It does not establish that the intervention is affordable, clinically acceptable, equitable, feasible to implement or supported by sufficiently reliable evidence.
Budget impact analysis separately estimates the financial consequences for a defined budget holder. Health technology assessment may also consider clinical evidence, uncertainty, equity, severity, implementation and other institutional criteria.
Common mistakes
These errors can make a correctly calculated INMB misleading. The comparison, units, threshold and decision context should therefore accompany the result.
- An INMB calculation is invalid when incremental costs and outcomes use different comparison directions.
- An INMB value is incomplete when the cost-effectiveness threshold is not reported.
- A positive INMB does not prove that an intervention is affordable.
- The alternative with the greatest probability of being cost-effective does not necessarily have the greatest expected net benefit.
- Pairwise INMB should not be used to omit relevant competing alternatives.
- A jurisdiction-specific threshold should not be presented as a universal value.
- A deterministic INMB should not be presented without appropriate uncertainty analysis.
Further learning
These verified Library resources explain net benefit, incremental analysis and decision-making under uncertainty. Final website links must use the confirmed Library destination or concept-filtered route for incremental-net-monetary-benefit rather than a guessed URL.
- Methods for the Economic Evaluation of Health Care Programmes — LIB-000001
- Applied Methods of Cost-Effectiveness Analysis in Healthcare — LIB-000003
- NICE Health Technology Evaluations: The Manual — LIB-000099
- NICE: Economic evaluation — LIB-000249
- Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis — LIB-000299
- Representing Uncertainty: The Role of Cost-Effectiveness Acceptability Curves — LIB-000300
Related Concepts (2)
Library
Publications
7
Methods for the Economic Evaluation of Health Care Programmes — Drummond, Sculpher, Claxton, Stoddart & Torrance, 4th Edition ed., 2015 (Oxford University Press)
The standard international reference text for economic evaluation methods in health care, covering cost-effectiveness, cost-utility and cost-benefit analysis, measurement of costs and outcomes, evidence synthesis, and the characterisation of uncertainty.
BookView source →Applied Methods of Cost-Effectiveness Analysis in Healthcare — Gray, Clarke, Wolstenholme & Wordsworth, 1st Edition ed., 2011 (Oxford University Press)
A practical, worked-example guide to conducting cost-effectiveness analysis, structured around outcomes, costs, modelling with decision trees and Markov models, and presenting results. Volume 3 in the Handbooks in Health Economic Evaluation series, developed from the University of Oxford course.
BookView source →Cost-Effectiveness in Health and Medicine — Neumann, Sanders, Russell, Siegel & Ganiats, 2nd Edition ed., 2016 (Oxford University Press)
The revised report of the Second Panel on Cost-Effectiveness in Health and Medicine, providing methodological benchmarks for CEA including the reference case, perspectives, discounting, and the valuation of health outcomes.
BookView source →NICE Health Technology Evaluations: The Manual (PMG36) — National Institute for Health and Care Excellence, PMG36 ed., 2022 (NICE)
NICE’s consolidated methods and processes manual for health technology evaluation, defining the reference case for economic evaluation (perspective, comparators, time horizon, discounting, EQ-5D, cost-effectiveness thresholds and the severity modifier) — the authoritative HTA methods reference for the English NHS.
Guidelines for the Economic Evaluation of Health Technologies: Canada, 4th Edition — Canadian Agency for Drugs and Technologies in Health (CADTH), 4th Edition ed., 2017 (CADTH / CDA-AMC)
CADTH’s national methods guidelines for the economic evaluation of health technologies in Canada — reference case, comparators, modelling, effectiveness, discounting and uncertainty — a major national HTA methods reference (co-authored with Sculpher and other leading health economists).
Net Health Benefits: A New Framework for the Analysis of Uncertainty in Cost-Effectiveness Analysis — Aaron A. Stinnett and John Mullahy, 18(2 Suppl):S68–S80 ed., 1998 (Medical Decision Making)
Foundational net-health-benefit framework for cost-effectiveness decisions under uncertainty.
Journal ArticleView source →Representing Uncertainty: The Role of Cost-Effectiveness Acceptability Curves — Elisabeth Fenwick, Karl Claxton and Mark Sculpher, 10(8):779–787 ed., 2001 (Health Economics)
Foundational explanation of cost-effectiveness acceptability curves and their proper role alongside expected net benefit.
Journal ArticleView source →
Economic evaluation — National Institute for Health and Care Excellence, Technology appraisal and highly specialised technologies guidance manual ed., 2026 (NICE)
Official methods guidance for comparative economic evaluation, including incremental analysis, ICERs, comparators and the treatment of dominated options.
Web GuidanceView source →
Frequently Asked Questions (6)
What is incremental net monetary benefit?
The monetary value of one intervention's incremental health effect over another at a set willingness-to-pay threshold, minus its incremental cost.
Source: Stinnett & Mullahy 1998
How is incremental net monetary benefit calculated?
The incremental health effect is multiplied by the threshold to convert it into money, and the incremental cost is subtracted. The result states in monetary terms how much better or worse one option is than the other at that willingness to pay. It is the monetary formulation of net benefit, distinguished from the net health formulation only in whether health is converted to money or cost is converted to health, and both produce identical rankings. The choice between the monetary and health formulations is usually made to suit the audience, since finance and clinical readers find different units more natural, and neither changes the recommendation.
Source: Stinnett & Mullahy 1998
Why does incremental net monetary benefit behave better than a ratio?
Because it is a linear function of the cost and effect differences, so its expected value across simulations equals the value calculated at the expected parameters, which is not true of ratios. That property allows the distribution to be summarised, confidence intervals to be constructed conventionally, and options to be ranked directly. Ratios lack all three properties, and they become undefined as the effect difference approaches zero regardless of how large the cost difference is. These properties are why probabilistic results are almost always computed in net benefit terms even when the headline figure is presented as a ratio, since the underlying statistics require a well-behaved quantity.
Source: Stinnett & Mullahy 1998
How is incremental net monetary benefit presented?
Usually as a plot against the threshold, since the figure changes with it and a single value would conceal that dependence. The point at which the line crosses zero is the threshold at which the preferred option changes, and it equals the incremental cost-effectiveness ratio. Confidence intervals around the line show the uncertainty at each threshold, which is a more complete presentation than an acceptability curve because it conveys magnitude as well as probability. The plot also makes visible whether the recommendation is robust across the plausible range of thresholds or holds only at one end of it, which a single figure cannot convey.
Source: Briggs, Claxton & Sculpher 2006
What does incremental net monetary benefit assume?
That health can be exchanged for money at a constant rate given by the threshold, which is the same assumption underlying any comparison of a ratio against a threshold, made explicit rather than implicit. It also assumes the threshold is known, which it frequently is not, and this is why results are reported across a range. Where the threshold itself is uncertain, that uncertainty is separate from parameter uncertainty and is normally handled by presentation rather than by simulation. Presenting results across a range of thresholds is therefore not a sensitivity analysis but a necessary part of reporting, since the figure is undefined until a threshold is chosen.
Source: Drummond et al. 2015
When is incremental net monetary benefit most useful?
Where the difference in effect between options is small relative to its uncertainty, since a ratio becomes uninformative there while net benefit remains well behaved. Where several options are compared, since it permits direct ranking without the sequential removal procedure. And where results are being combined across subgroups or across studies, since linear quantities can be aggregated and ratios cannot. It is also the natural quantity where results from several studies or subgroups are being combined, since linear measures can be aggregated in ways that ratios cannot. Meta-analysis of economic results, where it is attempted at all, therefore works in net benefit rather than in ratios.
Source: Stinnett & Mullahy 1998
Trust Record
Verified by User approval
Verification date: 9 Sep 2026, 17:07 UTC
Content version: 1.2.0
Canonical Identity
- Term code
- HE-EE-CEA-036
Stable URI · Machine-readable · Resolvable · CC BY 4.0